Skip Navigation

Cardiovascular Research 2003 59(3):538-548; doi:10.1016/S0008-6363(03)00468-1
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Smith, K. J
Right arrow Articles by Sane, D. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, K. J
Right arrow Articles by Sane, D. C
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

The cardiovascular effects of erythropoietin

Kyle J Smith, Anthony J Bleyer, William C Little and David C Sane*

Sections of Cardiology and Nephrology, Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045, USA

dsane{at}wfubmc.edu

* Corresponding author. Tel.: +1-336-716-7533; fax: +1-336-716-9188.

Erythropoietin is a hypoxia-induced hormone that is essential for normal erythropoiesis. The production of recombinant human erythropoietin (rHuEpo) has revolutionized the treatment of anemia associated with chronic renal failure and chemotherapy, and has been used as prophylaxis to prevent anemia after surgery. The erythropoietin receptor is widely distributed in the cardiovascular system, including endothelial cells, smooth muscle cells and cardiomyocytes. Epo has potentially beneficial effects on the endothelium including anti-apoptotic, mitogenic and angiogenic activities. On the other hand, some reports suggest that rHuEpo may have pro-thrombotic or platelet-activating effects. Hypertension develops in 20–30% of renal patients treated with rHuEpo. Many patients with heart failure have anemia. Despite some potential adverse effects, early studies in heart failure patients with anemia suggest that rHuEpo therapy is safe and effective in reducing left ventricular hypertrophy, enhancing exercise performance and increasing ejection fraction. Further studies are warranted to define the role of rHuEpo in chronic heart failure and other cardiovascular settings.

KEYWORDS Angiogenesis; Endothelial function; Platelets; Renal function; Thrombosis/embolism


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
K. Smith, D. Semple, S. Bhandari, and A.-M. L. Seymour
Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?
Eur J Heart Fail, August 1, 2009; 11(8): 732 - 738.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. J. Doyle, C. S. Rihal, D. A. Gastineau, and D. R. Holmes Jr
Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention implications for contemporary practice.
J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2019 - 2027.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
N. Toda, K. Ayajiki, and T. Okamura
Cerebral Blood Flow Regulation by Nitric Oxide: Recent Advances
Pharmacol. Rev., March 1, 2009; 61(1): 62 - 97.
[Abstract] [Full Text] [PDF]


Home page
JBJSHome page
J. C. Elfar, J. A. Jacobson, J. E. Puzas, R. N. Rosier, and M. J. Zuscik
Erythropoietin Accelerates Functional Recovery After Peripheral Nerve Injury
J. Bone Joint Surg. Am., August 1, 2008; 90(8): 1644 - 1653.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. E. van Albada, G. J. du Marchie Sarvaas, J. Koster, M. C. Houwertjes, R. M. F. Berger, and R. G. Schoemaker
Effects of erythropoietin on advanced pulmonary vascular remodelling
Eur. Respir. J., January 1, 2008; 31(1): 126 - 134.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Joyeux-Faure
Cellular Protection by Erythropoietin: New Therapeutic Implications?
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 759 - 762.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. S. Francis and A. Kanderian
Anemia and Heart Failure: A New Pathway?
J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1666 - 1667.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Lindenblatt, M. D. Menger, E. Klar, and B. Vollmar
Darbepoetin-Alpha Does Not Promote Microvascular Thrombus Formation in Mice: Role of eNOS-Dependent Protection Through Platelet and Endothelial Cell Deactivation
Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1191 - 1198.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. V. d'Uscio, L. A. Smith, A. V. Santhanam, D. Richardson, K. A. Nath, and Z. S. Katusic
Essential Role of Endothelial Nitric Oxide Synthase in Vascular Effects of Erythropoietin
Hypertension, May 1, 2007; 49(5): 1142 - 1148.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
K. E. Jie, M. C. Verhaar, M.-J. M. Cramer, K. van der Putten, C. A. J. M. Gaillard, P. A. Doevendans, H. A. Koomans, J. A. Joles, and B. Braam
Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors
Am J Physiol Renal Physiol, November 1, 2006; 291(5): F932 - F944.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Fandrey
A cordial affair - erythropoietin and cardioprotection
Cardiovasc Res, October 1, 2006; 72(1): 1 - 2.
[Full Text] [PDF]


Home page
Eur Heart JHome page
S. Hamed, I. Barshack, G. Luboshits, D. Wexler, V. Deutsch, G. Keren, and J. George
Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy
Eur. Heart J., August 1, 2006; 27(15): 1876 - 1883.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. S. Go, J. Yang, L. M. Ackerson, K. Lepper, S. Robbins, B. M. Massie, and M. G. Shlipak
Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study
Circulation, June 13, 2006; 113(23): 2713 - 2723.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. I. Schafer
Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia
Blood, June 1, 2006; 107(11): 4214 - 4222.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
L. H. Caramuru, A. A. Lopes, N. Y. Maeda, V. D. Aiello, and C. C. Filho
Long-term Behavior of Endothelial and Coagulation Markers in Eisenmenger Syndrome
Clinical and Applied Thrombosis/Hemostasis, April 1, 2006; 12(2): 175 - 183.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Miki, T. Miura, T. Yano, A. Takahashi, J. Sakamoto, M. Tanno, H. Kobayashi, Y. Ikeda, M. Nishihara, K. Naitoh, et al.
Alteration in Erythropoietin-Induced Cardioprotective Signaling by Postinfarct Ventricular Remodeling
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 68 - 75.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Moon, M. Krawczyk, D. Paik, T. Coleman, M. Brines, M. Juhaszova, S. J. Sollott, E. G. Lakatta, and M. I. Talan
Erythropoietin, Modified to Not Stimulate Red Blood Cell Production, Retains Its Cardioprotective Properties
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 999 - 1005.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C. J. Malkin, P. J. Pugh, J. N. West, E. J.R. van Beek, T. H. Jones, and K. S. Channer
Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial
Eur. Heart J., January 1, 2006; 27(1): 57 - 64.
[Abstract] [Full Text] [PDF]


Home page
J Oncol Pharm PractHome page
M. Milano and R. Collomp
Erythropoietin and neuroprotection: a therapeutic perspective
Journal of Oncology Pharmacy Practice, December 1, 2005; 11(4): 145 - 149.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
J. George, E. Goldstein, A. Abashidze, D. Wexler, S. Hamed, H. Shmilovich, V. Deutsch, H. Miller, G. Keren, and A. Roth
Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner
Cardiovasc Res, November 1, 2005; 68(2): 299 - 306.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. L. Clark and J. G.F. Cleland
Anemia and Chronic Heart Failure: Are We Asking the Right Questions?
Circulation, September 20, 2005; 112(12): 1681 - 1683.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
J. George, S. Patal, D. Wexler, A. Abashidze, H. Shmilovich, T. Barak, D. Sheps, and G. Keren
Circulating Erythropoietin Levels and Prognosis in Patients With Congestive Heart Failure: Comparison With Neurohormonal and Inflammatory Markers
Arch Intern Med, June 13, 2005; 165(11): 1304 - 1309.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Namiuchi, Y. Kagaya, J. Ohta, N. Shiba, M. Sugi, M. Oikawa, H. Kunii, H. Yamao, N. Komatsu, M. Yui, et al.
High Serum Erythropoietin Level Is Associated With Smaller Infarct Size in Patients With Acute Myocardial Infarction Who Undergo Successful Primary Percutaneous Coronary Intervention
J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1406 - 1412.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. S. Sabatine, D. A. Morrow, R. P. Giugliano, P. B.J. Burton, S. A. Murphy, C. H. McCabe, C. M. Gibson, and E. Braunwald
Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes
Circulation, April 26, 2005; 111(16): 2042 - 2049.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. O. Ventura and M. R. Mehra
Improvement of heart failure after renal transplantation: The complex maze of cardio-renal interaction
J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1061 - 1063.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
F. Scalera, J. T. Kielstein, J. Martens-Lobenhoffer, S. C. Postel, M. Tager, and S. M. Bode-Boger
Erythropoietin Increases Asymmetric Dimethylarginine in Endothelial Cells: Role of Dimethylarginine Dimethylaminohydrolase
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 892 - 898.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Aicher, A. M. Zeiher, and S. Dimmeler
Mobilizing Endothelial Progenitor Cells
Hypertension, March 1, 2005; 45(3): 321 - 325.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
P. van der Meer, E. Lipsic, R. H. Henning, R. A. de Boer, A. J.H. Suurmeijer, D. J. van Veldhuisen, and W. H. van Gilst
Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury
Eur J Heart Fail, December 1, 2004; 6(7): 853 - 859.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. M. Geiger, G. M. Fischberg, W. Chen, and L. Bernstein
Stroke Risk and Tamoxifen Therapy for Breast Cancer
J Natl Cancer Inst, October 20, 2004; 96(20): 1528 - 1536.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. A Bogoyevitch
An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection
Cardiovasc Res, August 1, 2004; 63(2): 208 - 216.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.